论文部分内容阅读
测定28例缺氧性肺动脉高压患者和23例正常人的血管紧张素Ⅰ、Ⅱ(ATⅠ及ATⅡ)及血管紧张素转化酶(ACE),并对其中8例患者进行了巯甲丙脯酸治疗试验。结果显示缺氧性肺动脉高压患者与正常对照组相比,其血浆ATⅡ水平明显升高,血清ACE活性明显降低;常规疗法对降低患者的ATⅡ水平和平均肺动脉压(mPAP)的作用不大,而加用巯甲丙脯酸后可使ACE活性进一步降低,从而明显降低ATⅡ和mPAP。由此表明ATⅡ在缺氧性肺动脉高压的发病中起着重要的作用,而巯甲丙脯酸则可能是一种治疗该症的有效药物。
Angiotensin Ⅰ, Ⅱ (ATⅠand ATⅡ) and angiotensin converting enzyme (ACE) were determined in 28 patients with hypoxic pulmonary hypertension and 23 normal controls, and 8 patients were treated with captopril test. The results showed that compared with the normal control group, the plasma ATⅡ level was significantly increased and the serum ACE activity was significantly decreased in the patients with hypoxic pulmonary hypertension. The conventional therapy had little effect on reducing ATⅡ level and mean pulmonary arterial pressure (mPAP) Addition of captopril can further reduce ACE activity, thereby significantly reducing AT Ⅱ and mPAP. This shows that AT Ⅱ plays an important role in the pathogenesis of hypoxic pulmonary hypertension, while captopril may be an effective drug for the treatment of this disease.